Recently, the "11th five-year plan" state-level "biotechnology new drug pilot test amplification, isolation and purification technology innovation and research platform" jointly applied with the third military medical university has been approved, and all funds have been fully funded. The construction of this technology platform will more vigorously promote the company's advantages in biotechnology drug development, especially in the pilot scale process amplification. The company will give full play to its own advantages, make rational use of external resources, and strive to build the company into a first-class biotechnology drug research and development innovation platform in western China and even in China.